Provided by Tiger Trade Technology Pte. Ltd.

AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF

26.97
-0.0300-0.11%
Volume:791
Turnover:21.35K
Market Cap:5.39M
PE:- -
High:26.97
Open:26.97
Low:26.97
Close:27.00
52wk High:27.94
52wk Low:22.63
Shares:200.00K
Float Shares:200.00K
Volume Ratio:1.87
T/O Rate:0.40%
Dividend:0.41
Dividend Rate:1.53%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Scholar Rock price target raised to $64 from $58 at Wedbush

TIPRANKS
·
Aug 21

Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance

TIPRANKS
·
Aug 21

Scholar Rock Holding Corporation - Prepared for U.S. Apitegromab Launch upon FDA Approval by Sept 30, 2026 Pdufa Date

THOMSON REUTERS
·
Aug 21

Scholar Rock Holding Corporation - Withdraws Apitegromab Maa in Europe; to Resubmit with Alternate Fill-Finish Facility

THOMSON REUTERS
·
Aug 21

Scholar Rock Holding Corporation - Pmda Agrees no Additional Clinical Studies Required; Scholar Rock to Submit Apitegromab Jnda by Ye 2026

THOMSON REUTERS
·
Aug 21

Scholar Rock Withdraws EU Apitegromab Filing After FDA Flags Catalent Indiana Plant with OAI Inspection Rating

Reuters
·
Aug 21

Pharma Stocks Have Rallied. 2 Stocks to Avoid-and 2 to Buy.

Dow Jones
·
Aug 21

Hims & Hers Health (HIMS) Lifts Guidance As Scrutiny Builds, Is The Stock Fully Valued?

Simply Wall St.
·
Aug 21

Hims & Hers Chief Legal Officer Soleil Boughton Disposes of USD 691,808 in Common Shares

Reuters
·
Aug 21

Eli Lilly Advances Early-Stage Eloralintide Trial: What Investors Should Watch

TIPRANKS
·
Aug 21

Eli Lilly’s Lebrikizumab Trial Completion Signals New Growth Path in Atopic Dermatitis

TIPRANKS
·
Aug 21

Eli Lilly Revenue Jumps 48% as Mounjaro and Zepbound Sales Reach $14.9B

TradingKey
·
Aug 20

Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines

Reuters
·
Aug 20

Barclays Sees Hims Sales Growth Amid Near-Term Profit Pressure

Reuters
·
Aug 20

Novonesis Expects Results from Weight-Loss Drug Supplement Study in 2027

Reuters
·
Aug 20

7 Growth Stocks Holding up in a Tough Market

Dow Jones
·
Aug 20

Will Foundayo’s UK GLP‑1 Approval and New R&D Deals Change Eli Lilly's (LLY) Narrative?

Simply Wall St.
·
Aug 20

Amplitude Therapeutics: Lilly to GET Exclusive, Target-Specific Rights to Develop ,Commercialize Licensed Products Directed to Collaboration Targets

THOMSON REUTERS
·
Aug 20

Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying Rna Vaccines for Infectious Diseases

THOMSON REUTERS
·
Aug 20

Amplitude: Initial Programs Target Infectious Diseases with High Unmet Need, with Lilly Retaining Options for up to Two Additional Targets

THOMSON REUTERS
·
Aug 20